Cannacord Genuity analyst Sumant Kulkarni has upgraded shares of Biogen Inc. from “hold” to “buy” despite skepticism concerning the approvability of the company’s Alzheimer’s drug. The analyst also increased his price target from $305 to $360. In a note, Kulkarni wrote that even the aducanumab skeptics agree for a variety of reasons it has a … Continue reading “Canaccord Analyst Gives “Buy” Rating on Biogen Despite Skepticism on Its Alzheimer’s Drug Getting Approved”
